Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Investigational Seasonal Affective Disorder (SAD) Drug
Investigational Seasonal Affective Disorder Drug · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Investigational Seasonal Affective Disorder (SAD) Drug | DRUG | - |
Inclusion Criteria: (Patient must meet these criteria in order to be eligible for this study.) * Patient has a history of Major Depressive Disorder (MDD) with a seasonal pattern. Exclusion Criteria: (Patient cannot meet these criteria in order to be eligible for this study.) * Patient has a curre...
The Investigational Seasonal Affective Disorder Drug is a small molecule in Phase 3 development for Seasonal Affective Disorder (SAD), a form of depression that follows a seasonal pattern. It is being developed by GSK plc and has been studied in a completed Phase 3 trial conducted in the United States and Canada.
It is being developed for the treatment or prevention of Seasonal Affective Disorder (SAD), a psychiatric condition. The completed Phase 3 study enrolled adults aged 18 years and older with SAD. It is investigational and has not been established as an approved therapy for this indication.
GSK plc, which trades under the ticker GSK, is the developer of the Investigational Seasonal Affective Disorder Drug. GSK is a global pharmaceutical company, and this small molecule asset sits within its psychiatry therapeutic area.
It is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active. The program is investigational and remains in clinical development rather than being an approved product.
The Investigational Seasonal Affective Disorder Drug has been studied in one completed Phase 3 trial, NCT00046449, titled Prevention of Seasonal Affective Disorder. The trial was randomized and double blind, with an uncontrolled design, and enrolled participants in the United States and Canada.
Yes. The Investigational Seasonal Affective Disorder Drug and the Investigational Seasonal Affective Disorder (SAD) Drug refer to the same GSK plc asset in Phase 3 development for Seasonal Affective Disorder. SAD is simply the abbreviation for the condition, Seasonal Affective Disorder.